Partner Headlines - AMRN

  1. UPDATE: WHat Amarin Would Need TO Disclose To Ensure Non-Misleading ...

    Benzinga
  2. First Amendment Decision a Win for Amarin and Physician Plaintiffs

    Benzinga
  3. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  4. Week Concludes With S&P 500 Below 2,000; Dow Below 17,000

    Benzinga
  5. Dow Falls Over 100 Points; Ulta Salon Shares Jump After Earnings ...

    Benzinga
  6. Conversant Shares Rise On Acquisition News; Health Care REIT ...

    Benzinga
  7. Markets Drop; Darden Adjusted Profit Beats Street View

    Benzinga
  8. Morning Market Losers

    Benzinga
  9. Amarin Moves Higher On Speculation Of Special Protocol Assessment

    Benzinga
  10. Top Performing Industries For June 12, 2014

    Benzinga
  11. FDA Approvals And Changes For The Week Ending February 14, 2 ...

    Benzinga
  12. Amarin Announces FDA DMEP Does Not Plan to Re-instate ANCHOR ...

    Benzinga
  13. Benzinga's Top #PreMarket Losers

    Benzinga
  14. Amarin Announces FDA Review Division Response on ANCHOR SPA Agreement ...

    Benzinga
  15. FDA Delays Decision on Amarin's Vascepa Drug

    Benzinga
  16. Amarin Receives FDA Notification That Action on ANCHOR sNDA Review ...

    Benzinga
  17. Amarin's Vascepa: Too Limited A Market Or FDA Blunder?

    Benzinga
  18. Amarin Announces Notification of Patent Allowances Related to ...

    Benzinga
  19. New Statin Rules: Which Drugmakers Had Ties?

    YCharts
  20. Is Amarin’s Fish Oil Blockbuster Dream Kaput?

    YCharts
  21. UPDATE: Citigroup Upgrades Amarin on Valuation

    Benzinga
  22. Benzinga's Top Upgrades

    Benzinga
  23. Aegis Capital Corp. Reiterates on Amarin Corporation plc After ...

    Benzinga
  24. Market Wrap For Thursday, October 17: S&P Record High On Debt ...

    Benzinga
  25. Mid-Day Market Update: SanDisk Surges On Upbeat Results; IBM ...

    Benzinga
  26. Mid-Morning Market Update: Markets Open Lower; Goldman Sachs ...

    Benzinga
  27. Stocks Hitting 52-Week Lows

    Benzinga
  28. UPDATE: Aegis Capital Downgrades Amarin Following Negative Panel ...

    Benzinga
  29. Benzinga's Top Pre-Market Losers

    Benzinga
  30. Amarin Announces Negative FDA Advisory Committee Outcome for ...

    Benzinga
  31. Amarin Halted Ahead of FDA Advisory Committee to Review sNDA ...

    Benzinga
  32. Aegis Says FDA's Outlook 'Not As Negative As People Think' on ...

    Benzinga
  33. Aegis Capital Reiterates Buy on Amarin Corporation Following ...

    Benzinga
  34. Jefferies Reiterates Buy on Amarin Corporation on Continued Positive ...

    Benzinga
  35. Goldman Sachs Reiterates Neutral on Amarin Ahead of Advisory ...

    Benzinga
  36. Amarin Shares Up 5% as FDA Says October 16th Advisory Committee ...

    Benzinga
  37. Enrollment in Amarin REDUCE-IT Cardiovascular Outcomes Study ...

    Benzinga
  38. Amarin Reports 30th Patent for Vascepa

    Benzinga
  39. Amarin Submits Supplemental NDA for Novasep as Fourth Vascepa ...

    Benzinga
  40. UPDATE: Citigroup Raises PT on Amarin Following Lighter 2Q13 ...

    Benzinga
  41. UPDATE: Jefferies Lowers PT on Amarin on Continued ANCHOR Partnership ...

    Benzinga
  42. Amarin Announces USPTO Allowance for Application 13/614,129 Related ...

    Benzinga
  43. Amarin Announces Patent Allowance Related to Vascepa and FDA ...

    Benzinga
  44. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus
  45. Benzinga's Top Pre-Market Gainers

    Benzinga
  46. Amarin Completes Dosing in a Fixed-Dose Combination Study With ...

    Benzinga
  47. Amarin Closes Dosing in Fixed-Dose Combination Study with Vascepa

    Benzinga
  48. FDA's Orange Book Doesn't Include Amarin's Vascepa NCE Status ...

    Benzinga
  49. Benzinga's Top Pre-Market Gainers

    Benzinga
  50. Amarin Receives Patent Allowance for Application 13/623,450 Related ...

    Benzinga
  51. Amarin Announces David Stack Appointed to Board of Directors

    Benzinga
  52. Amarin Spikes Lower

    Benzinga
  53. UDPATE: Aegis Capital Raises PT on Amarin to $35

    Benzinga
  54. Citigroup Reiterates Buy Rating, $20 PT on Amarin Corporation

    Benzinga
  55. Benzinga's Top Pre-Market Losers

    Benzinga
  56. UPDATE: Citigroup Initiates Amarin at Buy on Vascepa Overhang ...

    Benzinga
  57. Benzinga's Top Pre-Market Gainers

    Benzinga
  58. Amarin Awarded Patent 8,318,715 for Vascepa by USPTO

    Benzinga
  59. Amarin Announces USPTO has Published Notification of Notice of ...

    Benzinga
  60. A Peek Into The Market Before The Trading Starts

    Benzinga
  61. Amarin Announces US Patent 8,314,086 Award for Vascepa

    Benzinga
  62. Mid-Morning Market Update: Markets Rallying; J.C. Penney Misses ...

    Benzinga
  63. Amarin Awarded US Patent 8,298,554 Issuance for Vascepa

    Benzinga
  64. UPDATE: Wedbush Securities Downgrades Amarin Corporation to Neutral, ...

    Benzinga
  65. Benzinga's M&A Chatter for Tuesday September 11, 2012

    Benzinga
  66. Benzinga's M&A Chatter for Thursday September 6, 2012

    Benzinga
  67. Amarin Announces Notification of Patent Allowances for U.S. Applications ...

    Benzinga
  68. Amarin Announces Notification of Patent Allowance for Vascepa ...

    Benzinga
  69. Amarin Announces Additional Publication of MARINE Phase 3 Clinical ...

    Benzinga
  70. Health Care Sector Wrap

    FoxBusiness
  71. Benzinga's Top Pre-Market Gainers

    Benzinga
  72. Health Care Sector Wrap

    FoxBusiness
  73. Health Care Sector Wrap

    FoxBusiness
  74. Amarin Corporation (AMRN) Sees Spike in Option Activity with ...

    MarketIntelligenceCenter
  75. Amarin's

    IBD
  76. Facebook Inc. - Class A, Starbucks Among Stocks Down on High ...

    FoxBusiness
  77. Amarin Announces FDA Approval of Vascepa Capsules for the Reduction ...

    Benzinga
  78. Amarin and Horizon Pharma Higher Ahead of PDUFA Dates

    Benzinga
  79. Health Care Sector Wrap

    FoxBusiness
  80. Amarin Responds to Erroneous Website Posting

    Benzinga
  81. Biotechs With Upcoming PDUFA Dates

    Benzinga
  82. UPDATE: Aegis Capital Initiates Amarin Corporation with Buy, ...

    Benzinga
  83. New Annual Highs: AMRN, DIS, and NWS

    SchaeffersResearch
  84. Health Care Sector Wrap

    FoxBusiness
  85. Amarin (AMRN) Gains 10.5% As Company Appears Close to Winning ...

    MarketIntelligenceCenter
  86. Amarin Corporation plc, Loral Space & Communications Gapping ...

    FoxBusiness
  87. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT ...

    Benzinga
  88. CF Industries Holdings, SBA Communications Corporation Included ...

    FoxBusiness
  89. AMR101 Phase 3 Study Data in Patients With Diabetes Mellitus ...

    Benzinga
  90. Amarin Corporation plc (AMRN) Sees Above Average Option Activity ...

    MarketIntelligenceCenter
  91. Earnings Scheduled For May 8

    Benzinga
  92. Amarin

    IBD
  93. Amarin (AMRN) Up 20% on Patent News, Analyst Commentary

    MarketIntelligenceCenter
  94. Amarin Up 7% After FDA Announces it Will Not Convene FDA Panel ...

    Benzinga
  95. AMRN said the FDA accepted a new drug for review, while OII updated ...

    SchaeffersResearch
  96. Benzinga's M&A Chatter for Tuesday December 6, 2011

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!